Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Regulation of Pyruvate Kinase Type M2 by A-Raf: A Possible Glycolytic Stop or Go Mechanism

SYBILLE MAZUREK, HANNES C.A. DREXLER, JAKOB TROPPMAIR, ERICH EIGENBRODT and ULF R. RAPP
Anticancer Research November 2007, 27 (6B) 3963-3971;
SYBILLE MAZUREK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Sybille.Mazurek{at}vetmed.uni-giessen.de
HANNES C.A. DREXLER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JAKOB TROPPMAIR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ERICH EIGENBRODT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ULF R. RAPP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Recently a link between A-Raf, cellular energy homeostasis and synthetic pathways has been suggested through the identification of pyruvate kinase type M2 (M2-PK), a key glycolytic enzyme, as interaction partner of A-Raf. In this study, we demonstrated that A-Raf is an important regulator of M2-PK function. In primary mouse fibroblasts, which are characterized by glutamine production and serine degradation, A-Raf induced dimerization and inactivation of M2-PK, thereby reducing conversion rates from glucose to lactate. In immortalized NIH3T3 fibroblasts, showing glutamine degradation and serine production, oncogenic A-Raf increased the highly active tetrameric form of M2-PK and favored glycolytic energy production. High serine levels thus may be responsible for the activation of M2-PK in A-Raf transformed NIH3T3 cells.

  • A-Raf
  • pyruvate kinase
  • M2-PK
  • glutaminolysis
  • serinolysis
  • tumor metabolome

Footnotes

  • ↵+ Present address: Max Planck Institute for Molecular Biomedicine, Münster, Germany.

  • ↵* Shared last authorship.

  • ↵# Prof. Dr. Erich Eigenbrodt died in June 2004.

  • Received May 14, 2007.
  • Revision received August 22, 2007.
  • Accepted October 5, 2007.
  • Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 27, Issue 6B
November-December 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Regulation of Pyruvate Kinase Type M2 by A-Raf: A Possible Glycolytic Stop or Go Mechanism
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Regulation of Pyruvate Kinase Type M2 by A-Raf: A Possible Glycolytic Stop or Go Mechanism
SYBILLE MAZUREK, HANNES C.A. DREXLER, JAKOB TROPPMAIR, ERICH EIGENBRODT, ULF R. RAPP
Anticancer Research Nov 2007, 27 (6B) 3963-3971;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Regulation of Pyruvate Kinase Type M2 by A-Raf: A Possible Glycolytic Stop or Go Mechanism
SYBILLE MAZUREK, HANNES C.A. DREXLER, JAKOB TROPPMAIR, ERICH EIGENBRODT, ULF R. RAPP
Anticancer Research Nov 2007, 27 (6B) 3963-3971;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • NK92-exo Induces Ferroptosis in A549 Cells by Targeting a miR-663a-SLC11A2 Axis
  • PD-1+Tim-3+CD103+ CD8+ Tumor-infiltrating Lymphocytes Are Associated With Favorable Outcomes in Colorectal Cancer
  • Sulfasalazine an Inhibitor of System xC− (Cystine/glutamate Antiporter), Combined With Recombinant Methioninase, Inhibits Both Cancer and Normal Cells, Suggesting Lack of Cancer Selectivity of Cysteine Restriction
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire